EAACI Congress 2025
BackL-OAS-CT3 - Clinical Studies on Airways Diseases
Sunday 15 Jun, 15:45 PM -
17:15 PM Glasgow, United Kingdom
Innovation Hub
Oral Abstract Session on Clinical Trials
15:45
100176
Real-World Effectiveness of Dupilumab vs. Other Biologics in Achieving Clinical Remission as Assessed by a Composite Measure of Selected Asthma Outcomes in Patients with Severe Asthma: EU ADVANTAGE
15:57
100178
Dupilumab Reduces the Rate of Severe Exacerbations and Improves Lung Function in Children With Moderate-to-Severe Type 2 Asthma, Irrespective of Early Increases in Blood Eosinophil Counts
16:09
100239
Dupilumab Improves Small Airway Dysfunction in Patients With Moderate-to-Severe Asthma: The Phase 4 VESTIGE Study
16:21
100366
Efficacy and safety of dupilumab versus omalizumab in patients with severe chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): Results from a prospective, head-to-head phase 4 trial
16:33
100374
Mepolizumab provides sustained clinical benefits in patients with severe asthma regardless of age of asthma onset: Real-world data from the REALITI-A study at 2 years
